The BICRHOME study was a prospective, multicenter study enrolling 312 cirrhotic patients with BSI. In this secondary analysis we selected patients receiving TZP or carbapenems as adequate empiric treatment. The 30-day mortality of patients receiving C/EI or intermittent infusion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model and estimation of the average treatment effect (ATE) using propensity score matching.
Bartoletti, M., Giannella, M., Lewis, R.E., Caraceni, P., Tedeschi, S., Paul, M., et al. (2019). Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study. CLINICAL INFECTIOUS DISEASES, 69(10), 1731-1739 [10.1093/cid/ciz032].
Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study
Bartoletti, Michele;Giannella, Maddalena;Lewis, Russell E;Caraceni, Paolo;Tedeschi, Sara;Baldassarre, Maurizio;Verucchi, Gabriella;Domenicali, Marco;Bernardi, Mauro;Viale, Pierluigi
2019
Abstract
The BICRHOME study was a prospective, multicenter study enrolling 312 cirrhotic patients with BSI. In this secondary analysis we selected patients receiving TZP or carbapenems as adequate empiric treatment. The 30-day mortality of patients receiving C/EI or intermittent infusion of TZP or carbapenems was assessed with Kaplan-Meier curves, Cox-regression model and estimation of the average treatment effect (ATE) using propensity score matching.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bartoletti_2019.pdf
accesso aperto
Tipo:
Preprint
Licenza:
Licenza per Accesso Aperto. Altra tipologia di licenza compatibile con Open Access
Dimensione
1.24 MB
Formato
Adobe PDF
|
1.24 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
